Huons Global Co., Ltd.

KOSDAQ:A084110 Stock Report

Market Cap: ₩352.4b

Huons Global Valuation

Is A084110 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A084110 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A084110 (₩28900) is trading below our estimate of fair value (₩71253.55)

Significantly Below Fair Value: A084110 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A084110?

Key metric: As A084110 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for A084110. This is calculated by dividing A084110's market cap by their current earnings.
What is A084110's PE Ratio?
PE Ratio7.9x
Earnings₩44.94b
Market Cap₩352.38b

Price to Earnings Ratio vs Peers

How does A084110's PE Ratio compare to its peers?

The above table shows the PE ratio for A084110 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average16.8x
A041960 Komipharm International
24.3xn/a₩275.4b
A243070 Huons
7.5x15.3%₩299.8b
A003220 Daewon Pharmaceutical
19.5x45.6%₩312.5b
A216080 JETEMA
16x35.3%₩320.5b
A084110 Huons Global
7.9xn/a₩352.4b

Price-To-Earnings vs Peers: A084110 is good value based on its Price-To-Earnings Ratio (7.9x) compared to the peer average (16.8x).

Price to Earnings Ratio vs Industry

How does A084110's PE Ratio compare vs other companies in the KR Pharmaceuticals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
A007370 Jin Yang Pharmaceutical
2.4xn/aUS$48.87m
No more companies available in this PE range
A084110 7.9xIndustry Avg. 15.0xNo. of Companies8PE01224364860+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: A084110 is good value based on its Price-To-Earnings Ratio (7.9x) compared to the KR Pharmaceuticals industry average (15x).

Price to Earnings Ratio vs Fair Ratio

What is A084110's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A084110 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio7.9x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate A084110's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Bioneer

₩509.0b

Operates as a biotechnology company in South Korea, the Americas, Europe, Asia, Africa, and internationally.

A064550

₩19,910.00

7D

-0.7%

1Y

-34.6%

Hugel

₩3.0t

Develops and manufactures biopharmaceuticals in South Korea and internationally.

A145020

₩271,000.00

7D

-1.8%

1Y

76.5%

J2KBIO

₩53.0b

A bio venture company, provides active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation.

A420570

₩9,180.00

7D

-4.8%

1Y

n/a